Lil­ly be­comes the lat­est phar­ma to tap Ope­nAI for help, this time for an­tibi­ot­ic work

First it was Mod­er­na, then Sanofi, and now Lil­ly. Ope­nAI’s in­flu­ence on the phar­ma­ceu­ti­cal in­dus­try has made its way to In­di­anapo­lis.

Lil­ly Chief In­for­ma­tion Of­fi­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER